about
Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA.Delivering the promise of small ncRNA therapeutics.Nanomedicine therapeutics and diagnostics are the goal.Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route.Reprogramming of hepatic fat accumulation and 'browning' of adipose tissue by the short-chain fatty acid acetate.
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Delivery of RNAi therapeutics: work in progress.
@en
type
label
Delivery of RNAi therapeutics: work in progress.
@en
prefLabel
Delivery of RNAi therapeutics: work in progress.
@en
P2860
P1476
Delivery of RNAi therapeutics: work in progress.
@en
P2093
Andrew D Miller
P2860
P304
P356
10.1586/17434440.2013.855471
P577
2013-11-01T00:00:00Z